Protective Effect of Captopril, Olmesartan, Melatonin and Compound 21 on Doxorubicin-Induced Nephrotoxicity in Rats

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F13%3A10190735" target="_blank" >RIV/00216208:11150/13:10190735 - isvavai.cz</a>
Result on the web
<a href="http://www.biomed.cas.cz/physiolres/pdf/62/62_S181.pdf" target="_blank" >http://www.biomed.cas.cz/physiolres/pdf/62/62_S181.pdf</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Protective Effect of Captopril, Olmesartan, Melatonin and Compound 21 on Doxorubicin-Induced Nephrotoxicity in Rats
Original language description
The aim of this study was to compare the effect of melatonin and angiotensin II type 2 receptor agonist compound 21 (C21) to angiotensin converting enzyme inhibitor captopril and angiotensin II type 1 receptor blocker olmesartan on animal model of doxorubicin nephrotoxicity. Six groups of Wistar rats were treated for four weeks. The first group served as a control. The remaining groups were injected with a single dose of doxorubicin (5 mg/kg i.v.) at the same day as administration of either vehicle or captopril (100 mg/kg/day) or olmesartan (10 mg/kg/day) or melatonin (10 mg/kg/day) or C21 (0.3 mg/kg/day) was initiated. All four substances significantly diminished the level of oxidative burden and prevented the reduction of glomerular density. We conclude that captopril, olmesartan, melatonin and C21 exerted a similar level of renoprotective effects in doxorubicin-induced nephrotoxicity.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
ED - Physiology
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)